Mechanisms of persistent activation of the androgen receptor in CRPC: Recent advances and future perspectives

World Journal of Urology

Volumn 30, Issue 3, 2012, Pages 287-295

  Nadiminty, Nagalakshmi ^a   Gao, Allen C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgen receptor; Castration resistant prostate cancer; Cytokines; Intracrine androgens; Splice variants

Indexed keywords

ANDROGEN RECEPTOR;

ARTICLE; DISEASE COURSE; DRUG THERAPY; GENE AMPLIFICATION; GENETICS; HUMAN; MALE; MEDICAL RESEARCH; MUTATION; ORCHIECTOMY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION;

BIOMEDICAL RESEARCH; DISEASE PROGRESSION; DRUG THERAPY; GENE AMPLIFICATION; HUMANS; MALE; MUTATION; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84861649301     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-011-0771-3     Document Type: Article

References (99)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60: 277-300.
2. Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS (2006) Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res 66: 10613-10620.
3. Visakorpi T, Hyytinen E, Koivisto P et al (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9: 401-406.
4. Chen CD, Welsbie DS, Tran C et al (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39.
5. Palmberg C, Koivisto P, Kakkola L, Tammela TLJ, Kallioniemi OP, Visakorpi T (2000) Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 164: 1992-1995.
6. Scher HI, Sawyers CL (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23: 8253-8261.
7. Koochekpour S (2010) Androgen receptor signaling and mutations in prostate cancer. Asian J Androl 12: 639-657.
8. Brooke GN, Bevan CL (2009) The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 10: 18-25.
9. Buchanan G, Yang M, Cheong A et al (2004) Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet 13: 1677-1692.
10. Buchanan G, Yang M, Harris JM et al (2001) Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol Endocrinol 15: 46-56.
11. Taylor BS, Schultz N, Hieronymus H et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
12. Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME (2010) Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem 56: 1492-1495.
13. Steinkamp MP, O'Mahony OA, Brogley M et al (2009) Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade Therapy. Cancer Res 69: 4434-4442.
14. Tomlins SA, Bjartell A, Chinnaiyan AM et al (2009) ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 56: 275-286.
15. Tomlins SA, Mehra R, Rhodes DR et al (2006) TMPRSS2: ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 66: 3396-3400.
16. Morris DS, Tomlins SA, Montie JE, Chinnaiyan AM (2008) The discovery and application of gene fusions in prostate cancer. BJU Int 102: 276-282.
17. Demichelis F, Fall K, Perner S et al (2007) TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26: 4596-4599.
18. Attard G, Swennenhuis JF, Olmos D et al (2009) Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69: 2912-2918.
19. Klezovitch O, Risk M, Coleman I et al (2008) A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 105: 2105-2110.
20. Bastus NC, Boyd LK, Mao X et al (2010) Androgen-induced TMPRSS2: ERG fusion in nonmalignant prostate epithelial cells. Cancer Res 70: 9544-9548.
21. Fine SW, Gopalan A, Leversha MA et al (2010) TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol 23: 1325-1333.
22. Yu J, Yu J, Mani R-S et al (2010) An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17: 443-454.
23. Carver BS, Tran J, Gopalan A et al (2009) Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41: 619-624.
24. Yoshimoto M, Joshua AM, Cunha IW et al (2008) Absence of TMPRSS2: ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 21: 1451-1460.
25. Salami SS, Schmidt F, Laxman B et al Combining urinary detection of TMPRSS2: ERG and CaP3 with serum PSA to predict diagnosis of prostate cancer. Urologic oncology: seminars and original investigations. (in press, corrected proof).
26. Brenner JC, Ateeq B, Li Y et al (2011) Mechanistic rationale for inhibition of poly (ADP-Ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19: 664-678.
27. Wang Q, Carroll JS, Brown M (2005) Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell 19: 631-642.
28. Bulger M, Groudine M (1999) Looping versus linking: toward a model for long-distance gene activation. Genes Dev 13: 2465-2477.
29. Blackwood EM, Kadonaga JT (1998) Going the distance: the current view of enhancer action. Science 281: 60-63.
30. Wang Q, Li W, Liu XS et al (2007) A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 27: 380-392.
31. Wang Q, Li W, Zhang Y et al (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138: 245-256.
32. Hu R, Isaacs WB, Luo J (2011) A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate: n/a-n/a.
33. Tepper CG, Boucher DL, Ryan PE et al (2002) Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 62: 6606-6614.
34. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68: 5469-5477.
35. Guo Z, Yang X, Sun F et al (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69: 2305-2313.
36. Hu R, Dunn TA, Wei S et al (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69: 16-22.
37. Watson PA, Chen YF, Balbas MD et al Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. In: Proceedings of the national academy of sciences 107: 16759-16765.
38. Hornberg E, Ylitalo EB, Crnalic S et al (2011) Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 6: e19059.
39. Nishiyama T, Hashimoto Y, Takahashi K (2004) The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 10: 7121-7126.
40. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL (2005) Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11: 4653-4657.
41. Nakamura Y, Suzuki T, Nakabayashi M et al (2005) In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 12: 101-107.
42. Page ST, Lin DW, Mostaghel EA et al (2006) Persistent intraprostatic androgen concentrations after medical castration in healthy men. Clin Endocrinol Metab 91: 3850-3856.
43. Dillard PR, Lin M-F, Khan SA (2008) Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol 295: 115-120.
44. Mostaghel EA, Page ST, Lin DW et al (2007) Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67: 5033-5041.
45. Leon CG, Locke JA, Adomat HH et al (2010) Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 70: 390-400.
46. Pfeiffer MJ, Smit FP, Sedelaar JP, Schalken JA (2011) Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol Med. doi: 10. 2119/molmed. 2010. 00143.
47. Mostaghel EA, Nelson PS (2008) Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab 22: 243-258.
48. Hofland J, van Weerden WM, Dits NFJ et al (1999) Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res 70: 1256-1264.
49. Mostaghel EA, Montgomery B, Nelson PS (2009) Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol Oncol Semin Orig Investig 27: 251-257.
50. George DJ, Halabi S, Shepard TF et al (2005) The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res 11: 1815-1820.
51. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM (2001) Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 58: 1008-1015.
52. Corcoran NM, Costello AJ (2003) Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer? BJU Int 91: 545-553.
53. Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC (2007) Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate 67: 764-773.
54. Feng S, Tang Q, Sun M, Chun JY, Evans CP, Gao AC (2009) Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther 8: 665-671.
55. Ueda T, Mawji NR, Bruchovsky N, Sadar MD (2002) Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Chem Biol 277: 38087-38094.
56. Chun JY, Nadiminty N, Dutt S et al (2009) Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res 15: 4815-4822.
57. Culig Z Cytokine disbalance in common human cancers. Biochimica et Biophysica Acta (BBA). Mole Cell Res 1813: 308-314.
58. Santer FdrR, Malinowska K, Culig Z, Cavarretta IT (2010) Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer 17: 241-253.
59. Taguchi Y, Yamamoto M, Yamate T et al (1998) Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage. Proc Assoc Am Physicians 110: 559-574.
60. García-Moreno C, Méndez-Dávila C, de la Piedra C, Castro-Errecaborde NA, Traba ML (2002) Human prostatic carcinoma cells produce an increase in the synthesis of interleukin-6 by human osteoblasts. Prostate 50: 241-246.
61. Smith PC, Keller ET (2001) Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 48: 47-53.
62. Wallner L, Dai J, Escara-Wilke J et al (2006) Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res 66: 3087-3095.
63. Dorff TB, Goldman B, Pinski JK et al (2010) Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (Siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res 16: 3028-3034.
64. Karkera J, Steiner H, Li W et al (2011) The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate (Epub ahead of print).
65. Takeshi U, Sadar MD, Suzuki H et al (2005) Interleukin-4 in patients with prostate cancer. Anticancer Res 25: 4595-4598.
66. Lee SO, Lou W, Hou M, Onate SA, Gao AC (2003) Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene 22: 7981-7988.
67. Lee SO, Chun JY, Nadiminty N, Lou W, Feng S, Gao AC (2009) Interleukin-4 activates androgen receptor through CBP/p300. Prostate 69: 126-132.
68. Lee SO, Lou W, Nadiminty N, Lin X, Gao AC (2005) Requirement for NF-κB in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate 64: 160-167.
69. Lee SO, Pinder E, Chun JY, Lou W, Sun M, Gao AC (2008) Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. Prostate 68: 85-91.
70. Huang J, Yao JL, Zhang L et al (2005) Differential expression of interleukin-8 and Its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate can./cer. Am J Pathol 166: 1807-1815.
71. Veltri RW, Miller MC, Zhao G et al (1999) Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology 53: 139-147.
72. Seaton A, Scullin P, Maxwell PJ et al (2008) Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis 29: 1148-1156.
73. Lee L-F, Louie MC, Desai SJ et al (2004) Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene 23: 2197-2205.
74. Waugh DJJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14: 6735-6741.
75. MacManus CF, Pettigrew J, Seaton A et al (2007) Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells. Mol Cancer Res 5: 737-748.
76. Wilson C, Wilson T, Johnston PG, Longley DB, Waugh DJJ (2008) Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther 7: 2649-2661.
77. oB transcription and evasion of apoptosis. J Pharmacol Exp Ther 327: 746-759.
78. Singh R, Lokeshwar B (2009) Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs. Mol Cancer 8: 57.
79. Dhir R, Ni Z, Lou W, DeMiguel F, Grandis JR, Gao AC (2002) Stat3 activation in prostatic carcinomas. Prostate 51: 241-246.
80. Ok Lee S, Lou W, Qureshi KM, Mehraein-Ghomi F, Trump DL, Gao AC (2004) RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate 60: 303-309.
81. Matsuda T, Junicho A, Yamamoto T et al (2001) Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells. Biochem Biophys Res Commun 283: 179-187.
82. De Miguel F, Lee S, Onate S, Gao A (2003) Stat3 enhances transactivation of steroid hormone receptors. Nucl Recept 1: 3.
83. De Miguel F, Lee SO, Lou W et al (2002) Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice. Prostate 52: 123-129.
84. Huang H, Murphy T, Shu P, Barton A, Barton B (2005) Stable expression of constitutively-activated STAT3 in benign prostatic epithelial cells changes their phenotype to that resembling malignant cells. Mol Cancer 4: 2.
85. Ammirante M, Luo J-L, Grivennikov S, Nedospasov S, Karin M (2010) B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464: 302-305.
86. Palvimo JJ, Reinikainen P, Ikonen T, Kallio PJ, Moilanen A, Jänne OA (1996) Mutual transcriptional interference between RelA and androgen receptor. J Biol Chem 271: 24151-24156.
87. Cinar B, Yeung F, Konaka H et al (2004) Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells. Biochem J 379: 421-431.
88. Zhang L, Altuwaijri S, Deng F et al (2009) NF-[kappa]B regulates androgen receptor expression and prostate cancer growth. Am J Pathol 175: 489-499.
89. Jin RJ, Lho Y, Connelly L et al (2008) The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 68: 6762-6769.
90. Ishiguro H, Akimoto K, Nagashima Y et al (2009) aPKCε promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. Proc Natl Acad Sci 106: 16369-16374.
91. Rajasekhar VK, Studer L, Gerald W, Socci ND, Scher HI (2011) Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-[kappa]B signalling. Nat Commun 2: 162.
92. oB by TMPRSS2/ERG fusion isoforms through toll-like receptor-4. Cancer Res 71: 1325-1333.
93. Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F (2005) Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer 93: 1019-1023.
94. Nadiminty N, Chun JY, Lou W, Lin X, Gao AC (2008) NF-κB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation. Prostate 68: 1725-1733.
95. Lessard L, Saad F, Le Page C et al (2007) NF-[kappa]B2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells. Cell Signal 19: 1093-1100.
96. Nadiminty N, Lou W, Sun M et al (2010) Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res 70: 3309-3319.
97. Nadiminty N, Dutt S, Tepper C, Gao AC (2010) Microarray analysis reveals potential target genes of NF-κB2/p52 in LNCaP prostate cancer cells. prostate 70: 276-287.
98. Nadiminty N, Chun JY, Hu Y, Dutt S, Lin X, Gao AC (2007) LIGHT, a member of the TNF superfamily, activates Stat3 mediated by NIK pathway. Biochem Biophys Res Commun 359: 379-384.
99. oB p100 processing involves CBP/p300-mediated acetylation. Proc Natl Acad Sci 103: 7264-7269.